P/B
4,7
Adlai Nortye Ltd is a clinical-stage biotechnology company focused on the discovery and development of cancer therapies for patients across the spectrum of tumor types. The company has a robust pipeline of drug candidates which includes buparlisib (AN2025), palupiprant (AN0025), and AN4005 in the clinical stage, and AN8025, AN9025, and AN1025 in the preclinical stage.
Adlai Nortye Ltd is a clinical-stage biotechnology company focused on the discovery and development of cancer therapies for patients across the spectrum of tumor types. The company has a robust pipeline of drug candidates which includes buparlisib (AN2025), palupiprant (AN0025), and AN4005 in the clinical stage, and AN8025, AN9025, and AN1025 in the preclinical stage.
$1B
Market Cap • 9/25/2026
2004
(22 years)
Founded
2023
(3 years ago)
IPO
NASDAQ
Listing Exchange
China
Country
Valuation
P/S
55,4
P/EBITDA
—
P/OCF
—
P/FCF
—
P/E
—
BVPS
5,4
EPS
—
Market Cap
Market Cap
1B
EV
794M
EV/Revenue
44
EV/EBITDA
-35,6
EV/EBIT
-35,6
Payout
Dividend Per Share
0
Dividend Yield
0%
Buyback Yield
0%
Total Yield
0%
Payout
0%
Retained Earnings
-470,2M
Profitability
Gross Margin
100%
EBITDA Margin
—
EBIT Margin
—
Net Margin
—
D&A/EBITDA
0%
R&D/Revenue
178,4%
Capex/Revenue
0%
Capex/D&A
0%
Capex/OCF
0%
SBC/OCF
—
% PPE
1,1%
% Goodwill
0%
ROE
—
ROIC
—
Leverage
N.D./EBITDA
9,2
Debt/Equity
0%
Current Ratio
9,5
Quick Ratio
9,2
Interest Coverage
—
Premium
- Unrestricted access
- Unlimited data history
- Analysis videos
- Quarterly highlights
- Customizable financials table
- Ranking
- Discussions
...and much more!